aibioChina Resources Pharmaceutical plans RMB5 billion medium term notes
Tickers 3320
A wholly owned subsidiary received registration for up to RMB5 billion of medium term notes, valid for two years, with no issue announced yet.
Key facts
- Company
- China Resources Pharmaceutical Group Ltd. (HKEX: 3320)
- News type
- Debt Financing
- Primary source
- China Resources Pharmaceutical Group Limited announcement (2026-05-29)
China Resources Pharmaceutical Group Limited said on May 29, 2026 that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, received a notice of acceptance of registration for medium term notes. The notice was issued by the National Association of Financial Market Institutional Investors and carries the reference Zhong Shi Xie Zhu [2026] No. MTN455.
The notice is effective for two years from its issue date. During that period the subsidiary may issue medium term notes in tranches up to an aggregate amount of RMB5 billion. The company said the proceeds would mainly go to replenishing working capital and repaying interest-bearing debts, and to other purposes that comply with applicable laws and regulations.
The company said the proposed issuance may or may not proceed and that it will make further announcements as and when appropriate. The announcement names no placement agent, underwriter or advisor for the notes. Shareholders and potential investors were told to take care when dealing in the company's securities.